Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)

被引：0

作者：

Sehn, Laurie H. ^{[1
,2
]}

Luminari, Stefano ^{[3
,4
]}

Scholz, Christian W. ^{[5
]}

Huebel, Kai ^{[6
,7
,8
]}

Salar, Antonio ^{[9
]}

Paneesha, Shankara ^{[10
,11
]}

Wahlin, Bjorn E. ^{[12
]}

Panayiotidis, Panayiotis ^{[13
]}

Lee, Hui-Peng ^{[14
]}

Ubieto, Ana Jimenez ^{[15
]}

Sancho, Juan-Manuel ^{[16
]}

Kim, Tae Min ^{[17
]}

Domenech, Eva Domingo ^{[18
]}

Kumode, Takahiro ^{[19
]}

Poh, Christina ^{[20
]}

Thieblemont, Catherine ^{[21
]}

Deeren, Dries ^{[22
]}

de Wit, Edwin ^{[23
]}

Arbushites, Michael ^{[24
]}

Casadebaig, Marie-Laure ^{[23
]}

Trneny, Marek ^{[25
,26
]}

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Univ Modena & Reggio Emilia, Oncol & Regenerat Med, Surg Med & Dent Morphol Sci Related Transplant, Reggio Emilia, Italy

[4] Azienda USL IRCCS Reggio Emilia, Reggio Emilia, Italy

[5] Vivantes Klinikum Urban, Berlin, Germany

[6] Univ Cologne, Cologne, Germany

[7] Univ Hosp Cologne, Fac Med, Cologne, Germany

[8] Univ Hosp Cologne, Cologne, Germany

[9] Hosp Mar IMIM, Barcelona, Spain

[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, England

[11] Univ Birmingham, Birmingham, England

[12] Karolinska Univ Hosp, Stockholm, Sweden

[13] Natl & Kapodistrian Univ Athens, Gen Hosp LAIKO, Med Sch, Athens, Greece

[14] Flinders Med Ctr, Adelaide, Australia

[15] Hosp 12 Octubre, Serv Hematol, Madrid, Spain

[16] Univ Autonoma Bacrcelona, ICO IJC Hosp Germans Trias & Pujol, Barcelona, Spain

[17] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[18] Hosp Duran I Reynals, IDIBELL, Inst Catala Oncol, Barcelona, Spain

[19] Kindai Univ, Osaka, Japan

[20] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[21] St Paris Cite Univ, St Hosp, Assistance Publ Hop Paris, Paris, France

[22] AZ Delta Gen Hosp, Roeselare, Belgium

[23] Incyte Int Biosci, Sarl Morges, Switzerland

[24] Incyte Corp, Wilmington, DE USA

[25] Charles Univ Prague, Fac Med 1, Prague, Czech Republic

[26] Gen Hosp, Prague, Czech Republic

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-212970

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：LBA1 / LBA4

页数：4

共 50 条

[21] Bendamustine-120 plus rituximab therapy for relapsed or refractory follicular lymphoma: a multicenter phase II study
R Sakai
K Ohmachi
F Sano
R Watanabe
H Takahashi
H Takasaki
M Tanaka
Y Hattori
H Kimura
M Takimoto
T Tachibana
E Tanaka
Y Ishii
Y Ishiyama
M Hagihara
K Miyazaki
K Yamamoto
N Tomita
K Ando
Annals of Hematology, 2019, 98 : 2131 - 2138
[22] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
Batlevi, Connie Lee
Salles, Gilles
Park, Steven, I
Phillips, Tycel J.
Amengual, Jennifer E.
Andorsky, David
Campbell, Philip
McKay, Pamela
Leonard, John P.
Sondhi, Manu
Chen, Yingxue
Slatcher, Pamela L.
Lin, Richard
Szanto, Attila
Abbadi, Sara
Morschhauser, Franck
BLOOD, 2022, 140 : 2296 - 2298
[23] A Phase 1b/3 Randomized, Double-Blind, 3-Stage Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Leonard, John
Batlevi, Connie Lee
Gabrail, Nashat
Pagel, John M.
Yang, Jay
Whalen, Jennifer
Adib, Deyaa
Morschhauser, Franck
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S279 - S279
[24] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138
[25] Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
Chavez, Julio C.
Piris-Villaespesa, Miguel
Dalia, Samir
Powers, John
Turba, Elyce
Nodzon, Lisa
Komrokji, Rami
Sokol, Lubomir
Locke, Frederick L.
Lancet, Jeffrey
Sotomayor, Eduardo M.
Kharfan-Dabaja, Mohamed A.
Pinilla-Ibarz, Javier
LEUKEMIA RESEARCH, 2016, 47 : 78 - 83
[26] Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL).
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Coleman, Morton
Kolibaba, Kathryn S.
Brooks, Heather Dawn
Bitran, Jacob D.
Fanning, Suzanne R.
Lansigan, Frederick
Ricker, Justin L.
Foon, Kenneth A.
Liu, Dongfang
Llorente, Mary
Li, Jiahui
Sharman, Jeff Porter
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[27] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
Wang, Luhua
Fayad, Luis
Hagemeister, Fredrick B.
Neelapu, Sattva
Samaniego, Felipe
McLaughlin, Peter
Samuels, Barry
Yi, Qing
Pro, Barbara
Fanale, Michelle
Shah, Jatin
Younes, Anas
Bell, Neda
Knight, Robert
Zeldis, Jerome B.
Cabanillas, Fernando
Kwak, Larry
Romaguera, Jorge
BLOOD, 2009, 114 (22) : 1064 - 1065
[28] Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma
Rubenstein, James L.
Geng, Huimin
Fraser, Eleanor J.
Formaker, Paul
Chen, Lingjing
Sharma, Jigyasa
Killea, Phoebe
Choi, Kaylee
Ventura, Jenny
Kurhanewicz, John
Lowell, Clifford
Hwang, Jimmy
Treseler, Patrick
Sneed, Penny K.
Li, Jing
Wang, Xiaomin
Chen, Nianhang
Gangoiti, Jon
Munster, Pamela N.
Damato, Bertil
BLOOD ADVANCES, 2018, 2 (13) : 1595 - 1607
[29] Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Morschhauser, F.
Fowler, N. H.
Feugier, P.
Bouabdallah, R.
Tilly, H.
Palomba, M. L.
Fruchart, C.
Libby, E. N.
Casasnovas, R-O.
Flinn, I. W.
Haioun, C.
Maisonneuve, H.
Ysebaert, L.
Bartlett, N. L.
Bouabdallah, K.
Brice, P.
Ribrag, V.
Daguindau, N.
Le Gouill, S.
Pica, G. M.
Martin Garcia-Sancho, A.
Lopez-Guillermo, A.
Larouche, J-F.
Ando, K.
Gomes da Silva, M.
Andre, M.
Zachee, P.
Sehn, L. H.
Tobinai, K.
Cartron, G.
Liu, D.
Wang, J.
Xerri, L.
Salles, G. A.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (10): : 934 - 947
[30] Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M Wang
N Fowler
N Wagner-Bartak
L Feng
J Romaguera
S S Neelapu
F Hagemeister
M Fanale
Y Oki
B Pro
J Shah
S Thomas
A Younes
C Hosing
L Zhang
K J Newberry
M Desai
N Cheng
M Badillo
M Bejarano
Y Chen
K H Young
R Champlin
L Kwak
L Fayad
Leukemia, 2013, 27 : 1902 - 1909

← 1 2 3 4 5 →